A Phase 1, Open-Label, Dose Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of a first in class Pol1 inhibitor (CX-5461) in Patients with Advanced Haematologic Malignancies (HM) — Amit Khot (2015) | RDL Network
A Phase 1, Open-Label, Dose Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of a first in class Pol1 inhibitor (CX-5461) in Patients with Advanced Haematologic Malignancies (HM)
Simon J. Harrison, Amit Khot, Natalie Brajanovski, Donald P. Cameron, Nadine Hein, Grant A. McArthur, John K. C. Lim, Sean O’Brien, David M. Ryckman, Grace I Yu, Emma Link, Carrie Donohoe, Alicia Snowden, Narmatha Kuru, Ross D. Hannan
Amit Khot, Natalie Brajanovski, Donald P. Cameron, Gretchen Poortinga, Elaine Sanij, John Lim, John Soong, Nadine Hein, Emma Link, Richard B. Pearson, Ross D. Hannan, Grant A. McArthur, Simon J. Harrison
Amit Khot, Natalie Brajanovski, Donald P. Cameron, Nadine Hein, Kylee Maclachlan, Elaine Sanij, John K. C. Lim, John Soong, Emma Link, Piers Blombery, Ella R. Thompson, Andrew Fellowes, Karen E. Sheppard, Grant A. McArthur, Richard B. Pearson, Ross D. Hannan, Gretchen Poortinga, Simon J. Harrison
Amit Khot, Natalie Brajanovski, Donald P. Cameron, Nadine Hein, Kylee Maclachlan, Elaine Sanij, John Lim, John Soong, Emma Link, Piers Blombery, Ella R. Thompson, Andrew Fellowes, Karen E. Sheppard, Grant A. McArthur, Richard B. Pearson, Ross D. Hannan, Gretchen Poortinga, Simon J. Harrison
Amit Khot, Natalie Brajanovski, Donald P. Cameron, Nadine Hein, Kylee Maclachlan, Elaine Sanij, John Lim, John Soong, Emma Link, Piers Blombery, Ella R. Thompson, Andrew Fellowes, Karen E. Sheppard, Grant A. McArthur, Richard B. Pearson, Ross D. Hannan, Gretchen Poortinga, Simon J. Harrison
Discussion(0)
No comments yet. Be the first to comment.